Nanobiotix Initiates Patient Dosing in Innovative Cancer Study
PARIS and CAMBRIDGE, Mass. – In a significant advancement in cancer treatment, Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a pioneering company in nanoparticle-based therapies, has announced the first patient has been dosed in the CONVERGE study. This Phase 2 randomized clinical trial evaluates their innovative radioenhancer, JNJ-1900 (NBTXR3), for treating Stage 3 unresectable non-small cell lung cancer when paired with standard chemoradiation followed by consolidation durvalumab.
Understanding the CONVERGE Study
The CONVERGE study is crucial as it is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, ensuring rigorous investigation into the efficacy of JNJ-1900. The trial aims to provide valuable insights into how this product enhances existing therapeutic approaches for cancer patients, potentially improving outcomes for a significant patient population.
CEO Insights on the Study
Laurent Levy, CEO of Nanobiotix, emphasized the crucial role JNJ-1900 (NBTXR3) can play in cancer care. He stated, “The true value of JNJ-1900 lies in its ability to meet the significant unmet needs of countless patients requiring radiotherapy as part of their treatment.” This determination showcases the company's commitment to extending its innovative therapies to serious health challenges.
About JNJ-1900 (NBTXR3)
JNJ-1900, also known as NBTXR3, is a groundbreaking oncology product made from innovative hafnium oxide nanoparticles. It is administered through a one-time intratumoral injection and activated during radiotherapy. This method has demonstrated compelling proof-of-concept in treating soft tissue sarcomas, leading to a European CE mark in 2019.
Mechanism of Action and Its Implications
The unique mechanism of action of NBTXR3 is designed to induce elevated tumor cell death in targeted areas, enabling a robust adaptive immune response. Nanobiotix believes the scalable nature of NBTXR3 could extend its benefits across various solid tumors treated by radiotherapy, and allow it to be combined effectively with immune checkpoint inhibitors.
Ongoing Research and Development
Nanobiotix is not resting on its laurels as it explores a multitude of solid tumor applications. The radio-enhancer is being studied for safety and efficacy as either a standalone treatment or in conjunction with anti-PD-1 immune checkpoint inhibitors. Particularly notable is the global Phase 3 study NANORAY-312, which is focused on locally advanced head and neck squamous cell cancers.
Regulatory Milestones
A pivotal moment occurred in February 2020 when the U.S. Food and Drug Administration granted Fast Track designation to NBTXR3, facilitating its investigation as a radiation-activated therapy combined, or not, with cetuximab. This provision applies to patients with locally advanced HNSCC ineligible for standard chemotherapy, marking an important development in expanding treatment options.
Collaboration and Global Impact
To further its goals, Nanobiotix has engaged in a strategic collaboration with The University of Texas MD Anderson Cancer Center, sponsoring various Phase 1 and Phase 2 studies of NBTXR3 across multiple tumor types and treatment combinations. A significant milestone in 2023 includes a licensing agreement for global co-development with Janssen Pharmaceutica NV.
Company Philosophy and Vision
Moving beyond traditional treatment paradigms, Nanobiotix is committed to revolutionary, physics-based therapeutic strategies aimed at transforming treatment outcomes. Founded in 2003 and headquartered in Paris, France, the company is publicly traded on Euronext Paris and the Nasdaq Global Select Market, showcasing its expansive global outreach and research capabilities.
Frequently Asked Questions
What is the purpose of the CONVERGE study?
The CONVERGE study aims to evaluate the effectiveness of JNJ-1900 (NBTXR3) combined with standard chemoradiation therapies for treating Stage 3 unresectable non-small cell lung cancer.
Who is sponsoring the CONVERGE study?
The CONVERGE study is sponsored by Janssen Pharmaceutica NV, part of Johnson & Johnson, which ensures comprehensive oversight of the clinical trial.
What is NBTXR3 and how does it work?
NBTXR3 (JNJ-1900) is a novel oncology product made of hafnium oxide nanoparticles, activated by radiotherapy to induce significant tumor cell death and stimulate the immune response.
What are the implications of the FDA's Fast Track designation?
The Fast Track designation from the FDA facilitates the expedited development and review of NBTXR3, enhancing the potential for quicker access to treatment for patients with locally advanced HNSCC.
How is Nanobiotix expanding its research and development?
Nanobiotix fosters collaboration, engaging in multiple studies worldwide, and recently signed a licensing agreement with Janssen Pharmaceutica NV to boost the development of NBTXR3.
